In the NEOS trial, 40 patients with stage II-IIIB, EGFR-mutant NSCLC were enrolled and treated with neoadjuvant osimertinib, out of 38 assessable patients, the ORR and DCR was 71% and 100%, respectively, with 5% achieving pCR.[4] Seven (41.2 %) of the 17 resected patients with N2 disease at baseline experienced downstaging to N1 or N0 after neoadjuvant osimertinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.